The nasal polyp medication omalizumab (Xolair) improved sleep among patients with nasal polyposis, according to new data.

The research, supported by Novartis Pharmaceuticals and led by Eli O. Meltzer, MD, of the University of California, San Diego, assessed outcomes from the POLYP 1 and POLYP 2 trials which observed the monoclonal antibody plus background corticosteroids versus placebo in randomized patients with chronic rhinosinusitis with nasal polyps (CRSwNP) through 24 weeks.

“The present study suggests that omalizumab offers benefit for sleep disturbance for nasal polyposis, which is one of the most bothersome patient-reported symptoms of the disease,” investigators wrote.

The study, “The Impact of Omalizumab Therapy on Sleep in Patients With Nasal Polyps,” was presented at American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Virtual Sessions.

 The research, supported by Novartis Pharmaceuticals and led by Eli O. Meltzer, MD, of the University of California, San Diego, assessed outcomes from the POLYP 1 and POLYP 2 trials which observed the monoclonal antibody plus background corticosteroids versus placebo in randomized patients with chronic rhinosinusitis with nasal polyps (CRSwNP) through 24 weeks.

“The present study suggests that omalizumab offers benefit for sleep disturbance for nasal polyposis, which is one of the most bothersome patient-reported symptoms of the disease,” investigators wrote.

Get the full story at hcplive.com.